Phase II Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments for Patients With Advanced or Metastatic Non-small Cell Lung Cancer

What this Trial Is About

Researchers are evaluating the safety, tolerability, and objective response rate of SHR2554 tablets combined with other anti-tumor treatments in adults with locally advanced or metastatic non-small cell lung cancer. This phase II clinical trial aims to understand how well this combination works and its effects on this serious lung cancer condition. The study is sponsored by Jiangsu HengRui Medicine Co., Ltd. and follows an open-label, non-randomized design. The trial involves three experimental groups, each receiving SHR2554 tablets combined with a different anti-tumor treatment SHR-A2102 injection, Adabelimumab, or SHR-1701 injection. Treatments are given in 21-day cycles. Participants receive these combinations while researchers monitor their health and response to the therapy over time. Participants will be closely followed with assessments of side effects, serious adverse events, and tumor response from the first dose until disease progression or death, up to three years. Additional measures include immune response testing, duration of tumor response, disease control rate, progression-free survival, and overall survival. Safety is tracked from the first dose through 30 days after the last dose. The total participation time can last up to three years, with regular monitoring throughout.

Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects